Show simple item record

dc.contributor.authorWienhold, Sandra-Maria
dc.contributor.authorBrack, Markus C
dc.contributor.authorNouailles, Geraldine
dc.contributor.authorKrishnamoorthy, Gopinath
dc.contributor.authorKorf, Imke H E
dc.contributor.authorSeitz, Claudius
dc.contributor.authorWienecke, Sarah
dc.contributor.authorDietert, Kristina
dc.contributor.authorGurtner, Corinne
dc.contributor.authorKershaw, Olivia
dc.contributor.authorGruber, Achim D
dc.contributor.authorRoss, Anton
dc.contributor.authorZiehr, Holger
dc.contributor.authorRohde, Manfred
dc.contributor.authorNeudecker, Jens
dc.contributor.authorLienau, Jasmin
dc.contributor.authorSuttorp, Norbert
dc.contributor.authorHippenstiel, Stefan
dc.contributor.authorHocke, Andreas C
dc.contributor.authorRohde, Christine
dc.contributor.authorWitzenrath, Martin
dc.date.accessioned2022-02-11T10:41:19Z
dc.date.available2022-02-11T10:41:19Z
dc.date.issued2021-12-24
dc.identifier.citation. Viruses. 2021 Dec 24;14(1):33. doi: 10.3390/v14010033.en_US
dc.identifier.pmid35062236
dc.identifier.doi10.3390/v14010033
dc.identifier.urihttp://hdl.handle.net/10033/623162
dc.description.abstractRespiratory infections caused by multidrug-resistant Acinetobacter baumannii are difficult to treat and associated with high mortality among critically ill hospitalized patients. Bacteriophages (phages) eliminate pathogens with high host specificity and efficacy. However, the lack of appropriate preclinical experimental models hampers the progress of clinical development of phages as therapeutic agents. Therefore, we tested the efficacy of a purified lytic phage, vB_AbaM_Acibel004, against multidrug-resistant A. baumannii clinical isolate RUH 2037 infection in immunocompetent mice and a human lung tissue model. Sham- and A. baumannii-infected mice received a single-dose of phage or buffer via intratracheal aerosolization. Group-specific differences in bacterial burden, immune and clinical responses were compared. Phage-treated mice not only recovered faster from infection-associated hypothermia but also had lower pulmonary bacterial burden, lower lung permeability, and cytokine release. Histopathological examination revealed less inflammation with unaffected inflammatory cellular recruitment. No phage-specific adverse events were noted. Additionally, the bactericidal effect of the purified phage on A. baumannii was confirmed after single-dose treatment in an ex vivo human lung infection model. Taken together, our data suggest that the investigated phage has significant potential to treat multidrug-resistant A. baumannii infections and further support the development of appropriate methods for preclinical evaluation of antibacterial efficacy of phages.en_US
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAcinetobacter baumanniien_US
dc.subjectantibiotic resistanceen_US
dc.subjectbacteriophageen_US
dc.subjectpneumoniaen_US
dc.subjectpreclinical developmenten_US
dc.titlePreclinical Assessment of Bacteriophage Therapy against Experimental Lung Infection.en_US
dc.typeArticleen_US
dc.identifier.eissn1999-4915
dc.contributor.departmentHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.en_US
dc.identifier.journalVirusesen_US
dc.source.volume14
dc.source.issue1
refterms.dateFOA2022-02-11T10:41:19Z
dc.source.journaltitleViruses
dc.source.countrySwitzerland


Files in this item

Thumbnail
Name:
Wienhold et al.pdf
Size:
7.644Mb
Format:
PDF
Description:
Open Access publication
Thumbnail
Name:
Wienhold_suppl.zip
Size:
1.186Mb
Format:
Unknown
Description:
zipped supplementary information

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International